



# Nucala in India

*The CDSCO named-patient coordination pathway — indicative 2026*

IMMUNOLOGY · SEVERE EOSINOPHILIC ASTHMA, EGPA, HES, CRSWNP

## The clinical situation

Nucala (mepolizumab) is a subcutaneous anti-IL-5 monoclonal antibody FDA-approved for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP). Manufactured by GSK. Typical adult dosing is 100 mg SC every 4 weeks (higher in EGPA and HES). Pre-treatment workup confirms eosinophilic phenotype, screens for parasitic infection, and ensures vaccination currency per FDA labelling.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your pulmonologist, allergist, or immunologist documents indication, eosinophil counts, exacerbation history, and Nucala rationale.
- 2 Baseline screening.** Parasitic infection screen, vaccinations, and baseline eosinophil count documented per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; first dose administered with subsequent monthly maintenance.

### Indicative economics

**Reference US cash-pay range:** USD 3,500–4,200 per month of Nucala (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from GSK authorised distribution.

**Documentation.** Physician kit tailored to CDSCO review, with anti-IL-5 class safety annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through each monthly cycle. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Nucala × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/nucala-india.html](https://reservemed.com/access-guides/nucala-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team